|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for ALOX5 |
 Gene summary |
| Basic gene Info. | Gene symbol | ALOX5 |
| Gene name | arachidonate 5-lipoxygenase | |
| Synonyms | 5-LO|5-LOX|5LPG|LOG5 | |
| Cytomap | UCSC genome browser: 10q11.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_000698.3, NM_001256153.1,NM_001256154.1, | |
| Description | LOX-5arachidonic 5-lipoxygenase alpha-10 isoformarachidonic 5-lipoxygenase delta-10-13 isoformarachidonic 5-lipoxygenase delta-13 isoformarachidonic 5-lipoxygenase delta-p10 isoformarachidonic acid 5-lipoxygenaseleukotriene A4 synthase | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 152390 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000012779 | ||
| HPRD : 01065 | ||
| Vega : OTTHUMG00000018081 | ||
| Protein | UniProt: P09917 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_ALOX5 | |
| BioGPS: 240 | ||
| Pathway | NCI Pathway Interaction Database: ALOX5 | |
| KEGG: ALOX5 | ||
| REACTOME: ALOX5 | ||
| Pathway Commons: ALOX5 | ||
| Context | iHOP: ALOX5 | |
| ligand binding site mutation search in PubMed: ALOX5 | ||
| UCL Cancer Institute: ALOX5 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0019370 | leukotriene biosynthetic process | 21233389 |
| Top |
| Ligand binding site mutations for ALOX5 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | H373 | R371Q | COAD | 1 | H551,N555 | A553V | COAD | 1 | N555 | F556L | COAD | 1 | F178 | D177Y | LUAD | 1 | H373 | R371Q | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for ALOX5 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | N555 | F556L | 0.086211336 | H551 | A553V | -1.0476341 | N555 | A553V | -1.0476341 | H373 | R371Q | -0.98034046 | F178 | D177Y | -0.035728219 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for ALOX5 from PDB |
| Top |
| Differential gene expression and gene-gene network for ALOX5 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for ALOX5 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0004096 | Asthma | 32 | Biomarker, GeneticVariation |
| umls:C0004153 | Atherosclerosis | 18 | Biomarker, GeneticVariation |
| umls:C0009375 | Colonic Neoplasms | 5 | AlteredExpression, Biomarker, GeneticVariation |
| umls:C0023473 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | Biomarker, Therapeutic |
| umls:C0003873 | Arthritis, Rheumatoid | 4 | Biomarker |
| umls:C0027627 | Neoplasm Metastasis | 4 | Biomarker |
| umls:C0035126 | Reperfusion Injury | 3 | Biomarker |
| umls:C0042109 | Urticaria | 3 | Biomarker, GeneticVariation |
| umls:C0001430 | Adenoma | 3 | Biomarker |
| umls:C0020542 | Hypertension, Pulmonary | 2 | Biomarker |
| umls:C0009376 | Colonic Polyps | 2 | Biomarker, GeneticVariation |
| umls:C0009319 | Colitis | 1 | Biomarker |
| umls:C0011609 | Drug Eruptions | 1 | Biomarker |
| umls:C0376618 | Endotoxemia | 1 | Biomarker |
| umls:C0016659 | Fractures, Closed | 1 | Biomarker |
| umls:C0020429 | Hyperalgesia | 1 | Biomarker |
| umls:C0740392 | Infarction, Middle Cerebral Artery | 1 | Biomarker |
| umls:C0026766 | Multiple Organ Failure | 1 | Biomarker |
| umls:C0027626 | Neoplasm Invasiveness | 1 | Biomarker |
| umls:C0038356 | Stomach Neoplasms | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for ALOX5 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Approved|nutraceutical|vet_approved | DB00163 | Vitamin E | Small molecule |  |
| Approved | DB00179 | Masoprocol | Small molecule |  |
| Approved | DB00233 | Aminosalicylic Acid | Small molecule |  |
| Approved | DB00244 | Mesalazine | Small molecule |  |
| Approved | DB00471 | Montelukast | Small molecule |  |
| Approved|vet_approved | DB00586 | Diclofenac | Small molecule |  |
| Approved|vet_approved | DB00711 | Diethylcarbamazine | Small molecule |  |
| Approved|investigational|withdrawn | DB00744 | Zileuton | Small molecule |  |
| Approved | DB00795 | Sulfasalazine | Small molecule |  |
| Approved|vet_approved | DB00939 | Meclofenamic acid | Small molecule |  |
| Approved|investigational | DB01014 | Balsalazide | Small molecule |  |
| Approved|investigational | DB01017 | Minocycline | Small molecule |  |
| Nutraceutical | DB01892 | Hyperforin | Small molecule |  |
| Investigational | DB04725 | Licofelone | Small molecule |  |
| Investigational | DB05431 | MLN-977 | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of ALOX5 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of ALOX5 |
| Multiple alignments for P09917 in multiple species |
| LBS | AA sequence | # species | Species | F178 | EKGVDFVLNYS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F178 | LKMADFLGYSI | 2 | Oryza sativa subsp. japonica, Oryza sativa subsp. japonica | F178 | LKMSDFAGYSI | 1 | Oryza sativa subsp. japonica | F178 | VKFSDFLAYAL | 1 | Arabidopsis thaliana | F178 | LKMSDFLAYAL | 1 | Arabidopsis thaliana | H368 | HQTITHLLRTH | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | H368 | HQLISHWLNTH | 3 | Oryza sativa subsp. japonica, Oryza sativa subsp. japonica, Oryza sativa subsp. japonica | H368 | HQLISHWLQTH | 1 | Arabidopsis thaliana | H368 | HQLISHWMQTH | 1 | Arabidopsis thaliana | H373 | HLLRTHLVSEV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | H373 | HWLNTHAVMEP | 3 | Oryza sativa subsp. japonica, Oryza sativa subsp. japonica, Oryza sativa subsp. japonica | H373 | HWLQTHAVIEP | 1 | Arabidopsis thaliana | H373 | HWMQTHASIEP | 1 | Arabidopsis thaliana | H551 | TASAQHAAVNF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | H551 | IASALHAAVNF | 3 | Oryza sativa subsp. japonica, Oryza sativa subsp. japonica, Arabidopsis thaliana | H551 | IGSALHAAVNF | 1 | Oryza sativa subsp. japonica | H551 | VASALHAAVNF | 1 | Arabidopsis thaliana | I22 | ---DYIYLSLI | 2 | Mus musculus, Rattus norvegicus | I22 | ---DYIYLSLV | 1 | Homo sapiens | I22 | ITCQLVSATVA | 1 | Oryza sativa subsp. japonica | I22 | VTCQLISSTAV | 1 | Oryza sativa subsp. japonica | I22 | VTCQLVSSSLV | 1 | Oryza sativa subsp. japonica | I22 | VSLHLISSHQP | 1 | Arabidopsis thaliana | I22 | ITLRLVSSDVT | 1 | Arabidopsis thaliana | N555 | LHAAVNFGQYP | 5 | Oryza sativa subsp. japonica, Oryza sativa subsp. japonica, Oryza sativa subsp. japonica, Arabidopsis thaliana, Arabidopsis thaliana | N555 | QHAAVNFGQYD | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Q364 | DFHVHQTITHL | 2 | Homo sapiens, Mus musculus | Q364 | DSGWHQLISHW | 2 | Oryza sativa subsp. japonica, Oryza sativa subsp. japonica | Q364 | DFHIHQTITHL | 1 | Rattus norvegicus | Q364 | DYCWHQLISHW | 1 | Oryza sativa subsp. japonica | Q364 | DSGYHQLISHW | 1 | Arabidopsis thaliana | Q364 | DSGNHQLISHW | 1 | Arabidopsis thaliana |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |